Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
REVIEW

Acceptability of oral and topical HIV chemoprophylaxis in India: implications for at-risk women and men who have sex with men

Nomita Chandhiok A D , Smita N. Joshi B and Raman Gangakhedkar C
+ Author Affiliations
- Author Affiliations

A Indian Council of Medical Research, Ansari Nagar, New Delhi 110029, India.

B Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital Premises, 32 Sassoon Road, Pune 411001, India.

C National AIDS Research Institute, Bhosari, Pune 411026, India.

D Corresponding author. Email: n_chandhiok@hotmail.com

Sexual Health 11(2) 171-179 https://doi.org/10.1071/SH13067
Submitted: 1 May 2013  Accepted: 28 July 2013   Published: 11 October 2013

Abstract

With reducing HIV prevalence, India has made gains in containing the epidemic. Yet, unprotected sex and commercial sex work, unprotected anal sex between men and needle sharing among intravenous drug users continue to drive the epidemic. Development of effective, safe and acceptable topical (microbicides) and oral (pre-exposure prophylaxis (PrEP)) chemoprophylaxis could augment the already available tools for HIV prevention. This paper reviews the acceptability of topical microbicides and oral PrEP, in the context of the nature of the HIV epidemic, the sociocultural norms and the acceptability data obtained from studies carried out in India. Overall, men and women have a positive attitude towards the concept and use of microbicide products. Self-perceptions of HIV risk, product attributes, ease and convenience of use during sex, gender norms, the sociocultural context and the potential for undisclosed use were important factors influencing acceptability. A multipurpose product that would simultaneously address women’s contraceptive and disease prevention needs would be devoid of the stigma attached to an anti-HIV product and may be more acceptable. Limited information on the acceptability of oral PrEP amongst high-risk groups merits further research, including carrying out demonstration projects for program introduction.

Additional keywords: microbicides, pre-exposure prophylaxis, sex workers.


References

[1]  Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic 2012. Geneva: UNAIDS; 2012.

[2]  Joint United Nations Programme on HIV/AIDS (UNAIDS). Regional fact sheet 2012. Asia and the Pacific. Geneva: UNAIDS; 2012. Available online at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/2012_FS_regional_asia_pacific_en.pdf [verified May 2013].

[3]  National AIDS Control Organization. Technical report India. HIV estimates – 2012. New Delhi: Ministry of Health and Family Welfare, Government of India; 2012.

[4]  Department of AIDS Control. HIV Sentinel Surveillance 2010–11. A technical brief. New Delhi: Ministry of Health and Family Welfare, Government of India; 2012.

[5]  Sullivan PS, Carballo-Dieguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ, et al Successes and challenges of HIV prevention in men who have sex with men. Lancet 2012; 380 388–99.
Successes and challenges of HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 22819659PubMed |

[6]  Goswami P, Rachakulla HK, Ramakrishnan L, Mathew S, Ramanathan S, George B, et al An assessment of a large-scale HIV prevention programme for high-risk men who have sex with men and transgenders in Andhra Pradesh, India: using data from routine programme monitoring and repeated cross-sectional surveys. BMJ Open. 2013; 3 e002183
An assessment of a large-scale HIV prevention programme for high-risk men who have sex with men and transgenders in Andhra Pradesh, India: using data from routine programme monitoring and repeated cross-sectional surveys.Crossref | GoogleScholarGoogle Scholar | 23572195PubMed |

[7]  Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health 1990; 80 460–2.
HIV prevention: the need for methods women can use.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3c7ps1ChsQ%3D%3D&md5=07c05b88ccd78dbb65cc4d597bef716dCAS | 2316768PubMed |

[8]  Morison L, Weiss HA, Buvé A, Caraël M, Abega SC, Kaona F, et al Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. AIDS 2001; 15 S61–9.
Commercial sex and the spread of HIV in four cities in sub-Saharan Africa.Crossref | GoogleScholarGoogle Scholar | 11686467PubMed |

[9]  Brahme R, Mehta S, Sahay S, Joglekar N, Ghate M, Joshi S, et al Correlates and trend of HIV prevalence among female sex workers attending sexually transmitted disease clinics in Pune, India (1993–2002). J Acquir Immune Defic Syndr 2006; 41 107–13.
Correlates and trend of HIV prevalence among female sex workers attending sexually transmitted disease clinics in Pune, India (1993–2002).Crossref | GoogleScholarGoogle Scholar | 16340482PubMed |

[10]  Deering KN, Bhattacharjee P, Mohan HL, Bradley J, Shannon K, Boily MC, et al Violence and HIV risk among female sex workers in southern India. Sex Transm Dis 2013; 40 168–74.
| 23441335PubMed |

[11]  Reed E, Gupta J, Biradavolu M, Blankenship KM. Migration/mobility and risk factors for HIV among female sex workers in Andhra Pradesh, India: implications for HIV prevention. Int J STD AIDS 2012; 23 e7–13.
Migration/mobility and risk factors for HIV among female sex workers in Andhra Pradesh, India: implications for HIV prevention.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38nisl2rsg%3D%3D&md5=802b04b2a98cad324103f761479cbd6cCAS | 22581964PubMed |

[12]  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365 493–505.
HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhtVars7jF&md5=560e3d74f02174a6ddec3749d67d5bf8CAS | 21767103PubMed |

[13]  Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis 2012; 12 289
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 23130761PubMed |

[14]  Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329 1168–74.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXhtV2hsr%2FI&md5=edf775f75d124742a563d00fadc0976bCAS | 20643915PubMed |

[15]  Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections, 2013 March 3–6; Atlanta, GA, USA, Abstract 26LB.

[16]  FACTS Consortium. FACTS 001 study. Hillbrow: FACTS Consortium; 2013. Available online at: http://www.facts-consortium.co.za/?page_id=83 [verified May 2013].

[17]  Mantell JE, Myer L, Carballo-Diéguez A, Stein Z, Ramjee G, Morar NS, et al Microbicide acceptability research: current approaches and future directions. Soc Sci Med 2005; 60 319–30.
Microbicide acceptability research: current approaches and future directions.Crossref | GoogleScholarGoogle Scholar | 15522488PubMed |

[18]  Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav 2005; 9 121–31.
A framework for examining the sustained acceptability of microbicides.Crossref | GoogleScholarGoogle Scholar | 15812619PubMed |

[19]  Tolley E, Severy LJ. Behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health 2006; 96 79–83.
Behavioral and social science research into microbicide clinical trials: challenges and opportunities.Crossref | GoogleScholarGoogle Scholar | 16317214PubMed |

[20]  Greene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex 2010; 12 739–54.
Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India.Crossref | GoogleScholarGoogle Scholar | 20397080PubMed |

[21]  Joglekar N, Joshi S, Kakde M, Fang G, Cianciola M, Reynolds S, et al HIV Prevention Trial Network 047 Protocol Team Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care 2007; 19 817–21.
Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD2szlvFKnsQ%3D%3D&md5=8a62ee302a91b42bb224dae551772e6aCAS | 17573603PubMed |

[22]  Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, et al Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health 2004; 94 1159–64.
Acceptability of a microbicide among women and their partners in a 4-country phase I trial.Crossref | GoogleScholarGoogle Scholar | 15226137PubMed |

[23]  Tolley EE, Tsui S, Mehendale S, Weaver MA, Kohli R. Predicting product adherence in a topical microbicide safety trial in Pune, India. AIDS Behav 2012; 16 1808–15.
Predicting product adherence in a topical microbicide safety trial in Pune, India.Crossref | GoogleScholarGoogle Scholar | 21877203PubMed |

[24]  Dutta S, Joglekar N, Joshi S, Steven JR. Experience of conducting a phase I safety & acceptability clinical trial of a candidate vaginal microbicide & lessons learned. Indian J Med Res 2008; 128 212–3.
| 19001688PubMed |

[25]  Abbott SA, Friedland BA, Sarna A, Katzen LL, Rawiel U, Srikrishnan AK, et al An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India. AIDS Behav 2013; 17 2222–36.
An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India.Crossref | GoogleScholarGoogle Scholar | 23299877PubMed |

[26]  Kohli R, Tsui S, Mehendale S, Tolley E. Indian married men’s interest in microbicide use. AIDS Care 2011; 23 1344–9.
Indian married men’s interest in microbicide use.Crossref | GoogleScholarGoogle Scholar | 21711169PubMed |

[27]  Mensch BS, Friedland BA, Abbott SA, Katzen LL, Tun W, Kelly CA, et al Characteristics of female sex workers in southern India willing and unwilling to participate in a placebo gel trial. AIDS Behav 2013; 17 585–97.
Characteristics of female sex workers in southern India willing and unwilling to participate in a placebo gel trial.Crossref | GoogleScholarGoogle Scholar | 22907287PubMed |

[28]  Tolley EE, Eng E, Kohli R, Bentley ME, Mehendale S, Bunce A, et al Examining the context of microbicide acceptability among married women and men in India. Cult Health Sex 2006; 8 351–69.
Examining the context of microbicide acceptability among married women and men in India.Crossref | GoogleScholarGoogle Scholar | 16846943PubMed |

[29]  Joglekar NS, Joshi SN, Deshpande SS, Parkhe AN, Katti UR, Mehendale SM. Acceptability and adherence: findings from a phase II study of a candidate vaginal microbicide, ‘Praneem polyherbal tablet’, in Pune, India. Trans R Soc Trop Med Hyg 2010; 104 412–5.
Acceptability and adherence: findings from a phase II study of a candidate vaginal microbicide, ‘Praneem polyherbal tablet’, in Pune, India.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3czitl2lsw%3D%3D&md5=12d7e36cacd74110874eff955f811697CAS | 20096909PubMed |

[30]  Mehendale S, Deshpande S, Kohli R, Tsui S, Tolley E. Acceptability of coitally-associated versus daily use of 1% tenofovir vaginal gel among women in Pune, India. Int Health 2012; 4 63–9.
Acceptability of coitally-associated versus daily use of 1% tenofovir vaginal gel among women in Pune, India.Crossref | GoogleScholarGoogle Scholar | 24030882PubMed |

[31]  Joglekar NS, Joshi SN, Navlakha SN, Katti UR, Mehendale SM. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India – phase I study. Indian J Med Res 2006; 123 547–52.
| 1:STN:280:DC%2BD28zms1yhug%3D%3D&md5=74df19f09c2017e9b7b177ff6a5cd02cCAS | 16783046PubMed |

[32]  Darroch JE, Frost JJ. Women’s interest in vaginal microbicides. Fam Plann Perspect 1999; 31 16–23.
Women’s interest in vaginal microbicides.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1M7lsVWqsg%3D%3D&md5=2502908c29343a87228c22b510f95737CAS | 10029928PubMed |

[33]  Coggins C, Segal S. AIDS and reproductive health. J Reprod Immunol 1998; 41 3–15.
AIDS and reproductive health.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1M3ivVeisw%3D%3D&md5=3b73d2f465ad9ca1d1213512e3e561bfCAS | 10213297PubMed |

[34]  Ramjee G, Gouws E, Andrews A, Myer L, Weber AE. The acceptability of a vaginal microbicide among South African men. Int Fam Plan Perspect 2001; 27 164–170.
The acceptability of a vaginal microbicide among South African men.Crossref | GoogleScholarGoogle Scholar |

[35]  van de Wijgert JHHM, Khumalo-Sakutukwa GN, Coggins C, Dube SE, Nyamapfeni P, Mwale M, et al Men’s attitudes toward vaginal microbicides and microbicide trials in Zimbabwe. Int Fam Plan Perspect 1999; 25 15–20.
Men’s attitudes toward vaginal microbicides and microbicide trials in Zimbabwe.Crossref | GoogleScholarGoogle Scholar |

[36]  International Institute for Population Sciences (IIPS)National family health survey (NFHS-3), 2005–06: volume I. Mumbai: IIPS; 2006 .

[37]  Go VF, Sethulakshmi CJ, Bentley ME, Sivaram S, Srikrishnan AK, Solomon S, et al When HIV-prevention messages and gender norms clash: the impact of domestic violence on women’s HIV risk in slums of Chennai, India. AIDS Behav 2003; 7 263–72.
When HIV-prevention messages and gender norms clash: the impact of domestic violence on women’s HIV risk in slums of Chennai, India.Crossref | GoogleScholarGoogle Scholar | 14586189PubMed |

[38]  World Health Organisation (WHO). Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: WHO; 2012.

[39]  Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, et al Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363 2587–99.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXit1ansg%3D%3D&md5=b39a906c7240d79fdbeaf237f111f195CAS | 21091279PubMed |

[40]  Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367 423–34.
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtlSltrbE&md5=e81eb217c313fb5faddc4a243f3929efCAS | 22784038PubMed |

[41]  Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367 399–410.
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtlSltrbK&md5=a4f2585e592d6d40e1bdccda0bb5f4e4CAS | 22784037PubMed |

[42]  National Behavioural Sentinel Surveillance. Men who have sex with men (MSM) and injecting drug users (IDUs). New Delhi: National AIDS Control Organization; 2006.

[43]  Safren SA, Thomas BE, Mimiaga MJ, Chandrasekaran V, Menon S, Swaminathan S, et al Depressive symptoms and human immunodeficiency virus risk behavior among men who have sex with men in Chennai, India. Psychol Health Med 2009; 14 705–15.
Depressive symptoms and human immunodeficiency virus risk behavior among men who have sex with men in Chennai, India.Crossref | GoogleScholarGoogle Scholar | 20183543PubMed |

[44]  Thomas B, Mimiaga MJ, Menon S, Chandrasekaran V, Murugesan P, Swaminathan S, et al Unseen and unheard: predictors of sexual risk behavior and HIV infection among men who have sex with men in Chennai, India. AIDS Educ Prev 2009; 21 372–83.
Unseen and unheard: predictors of sexual risk behavior and HIV infection among men who have sex with men in Chennai, India.Crossref | GoogleScholarGoogle Scholar | 19670971PubMed |

[45]  Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE 2012; 7 e28238
Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhsVShs70%3D&md5=8a6b30431491526c9fd5d7e569b25399CAS | 22247757PubMed |

[46]  Schneider J, Kumar R, Dandona R, Kumar P, Kumar A, Lakshmi V, et al Social network and risk-taking behavior most associated with rapid HIV testing, circumcision, and preexposure prophylaxis acceptability among high-risk Indian men. AIDS Patient Care STDS 2012; 26 631–40.
Social network and risk-taking behavior most associated with rapid HIV testing, circumcision, and preexposure prophylaxis acceptability among high-risk Indian men.Crossref | GoogleScholarGoogle Scholar | 22973951PubMed |

[47]  Schneider JA, Dandona R, Pasupneti S, Lakshmi V, Liao C, Yeldandi V, et al Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers. PLoS ONE 2010; 5 e11922
Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers.Crossref | GoogleScholarGoogle Scholar | 20689602PubMed |

[48]  Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav 2013; 17 737–47.
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.Crossref | GoogleScholarGoogle Scholar | 23065145PubMed |

[49]  Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health (Larchmt) 2010; 19 791–8.
Acceptability of PrEP for HIV prevention among women at high risk for HIV.Crossref | GoogleScholarGoogle Scholar |

[50]  Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. PLoS ONE 2012; 7 e51080
Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVyisLrN&md5=8a2350b1c3cdec33454bf78327ff024cCAS | 23226560PubMed |

[51]  Maitra SS, Stephen L. Reflecting diversity and complexity in marital sexual relationships in a low income community in Mumbai. Cult Health Sex 2002; 4 133–51.
Reflecting diversity and complexity in marital sexual relationships in a low income community in Mumbai.Crossref | GoogleScholarGoogle Scholar |

[52]  Dai JY, Gilbert PB, Hughes JP, Brown ER. Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration. Am J Epidemiol 2013; 177 256–63.
Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration.Crossref | GoogleScholarGoogle Scholar | 23302152PubMed |

[53]  Estes LJ, Lloyd LE, Teti M, Raja S, Bowleg L, Allgood KL, et al Perceptions of audio computer-assisted self-interviewing (ACASI) among women in an HIV-positive prevention program. PLoS ONE 2010; 5 e9149
Perceptions of audio computer-assisted self-interviewing (ACASI) among women in an HIV-positive prevention program.Crossref | GoogleScholarGoogle Scholar | 20161771PubMed |

[54]  Mauck CK, Van de Straten A. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides. J Acquir Immune Defic Syndr 2008; 49 64–9.
Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides.Crossref | GoogleScholarGoogle Scholar | 18667920PubMed |

[55]  Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 2009; 36 368–71.
Limitations of the dye-based method for determining vaginal applicator use in microbicide trials.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXmt1aqtLc%3D&md5=fbfafc4fe155d7a53fa55dc740b6a854CAS | 19556930PubMed |

[56]  Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga Sgisi J, et al Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367 411–22.
Preexposure prophylaxis for HIV infection among African women.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtlSltrbL&md5=df1d56a010cad19fa9e2e66f54ccdc00CAS | 22784040PubMed |

[57]  Muchomba FM, Gearing RE, Simoni JM, El-Bassel NJ. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012; 61 490–8.
State of the science of adherence in pre-exposure prophylaxis and microbicide trials.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xhs1entb3K&md5=c5d171442a40d8dbd5a4e08dcbec9ed4CAS | 22932322PubMed |

[58]  Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I. Vaginal rings for delivery of HIV microbicides. Int J Womens Health. 2012; 4 595–605.
Vaginal rings for delivery of HIV microbicides.Crossref | GoogleScholarGoogle Scholar | 23204872PubMed |

[59]  Microbicide Trials Network (MTN). First combination ARV vaginal ring for HIV prevention being tested in phase I safety trial. Pittsburgh: MTN; 2011. Available online at: http://www.mtnstopshiv.org/node/3651 [verified June 2013].

[60]  Joshi S, Kulkarni V, Paranjape R, Chandhiok N. Challenges of introducing vaginal microbicides in India. Indian J Med Res 2009; 129 618–9.
| 19675395PubMed |

[61]  Panchanadeswaran S, Johnson SC, Sivaram S, Srikrishnan AK, Latkin C, Bentley ME, et al Intimate partner violence is as important as client violence in increasing street-based female sex workers’ vulnerability to HIV in India. Int J Drug Policy 2008; 19 106–12.
Intimate partner violence is as important as client violence in increasing street-based female sex workers’ vulnerability to HIV in India.Crossref | GoogleScholarGoogle Scholar | 18187314PubMed |

[62]  Panchanadeswaran S, Johnson SC, Sivaram S, Srikrishnan AK, Zelaya C, Solomon S, et al A descriptive profile of abused female sex workers in India. J Health Popul Nutr 2010; 28 211–20.
A descriptive profile of abused female sex workers in India.Crossref | GoogleScholarGoogle Scholar | 20635631PubMed |

[63]  Santhya KG, Acharya R, Jejeebhoy SJ. Condom use before marriage and its correlates: evidence from India. Int Perspect Sex Reprod Health 2011; 37 170–80.
Condom use before marriage and its correlates: evidence from India.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC387ivVenug%3D%3D&md5=2a1ecb3f8678f8e88b257c9c4deb9ba2CAS | 22227624PubMed |

[64]  Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS 2013; 27 248–54.
From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City.Crossref | GoogleScholarGoogle Scholar | 23565928PubMed |

[65]  Galindo GR, Walker JJ, Hazelton P, Lane T, Steward WT, Morin SF, et al Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci 2012; 7 116
Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation.Crossref | GoogleScholarGoogle Scholar | 23181780PubMed |

[66]  Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav 2013; 17 2162–72.
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.Crossref | GoogleScholarGoogle Scholar | 23080358PubMed |

[67]  Beattie TS, Bhattacharjee P, Suresh M, Isac S, Ramesh BM, Moses S. Personal, interpersonal and structural challenges to accessing HIV testing, treatment and care services among female sex workers, men who have sex with men and transgenders in Karnataka state, South India. J Epidemiol Community Health 2012; 66 ii42–8.
Personal, interpersonal and structural challenges to accessing HIV testing, treatment and care services among female sex workers, men who have sex with men and transgenders in Karnataka state, South India.Crossref | GoogleScholarGoogle Scholar | 22495772PubMed |

[68]  Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011; 8 62–72.
Combination HIV prevention: significance, challenges, and opportunities.Crossref | GoogleScholarGoogle Scholar | 20941553PubMed |

[69]  Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res Treat 2013; 2013 790154
| 1:STN:280:DC%2BC3srgtFaitg%3D%3D&md5=9855ffbed5c8224712e2b39a9d796705CAS | 23533733PubMed |